|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:TTLL5-APOE (FusionGDB2 ID:95173) |
Fusion Gene Summary for TTLL5-APOE |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: TTLL5-APOE | Fusion gene ID: 95173 | Hgene | Tgene | Gene symbol | TTLL5 | APOE | Gene ID | 254173 | 348 |
| Gene name | tubulin tyrosine ligase like 10 | apolipoprotein E | |
| Synonyms | TTLL5 | AD2|APO-E|ApoE4|LDLCQ5|LPG | |
| Cytomap | 1p36.33 | 19q13.32 | |
| Type of gene | protein-coding | protein-coding | |
| Description | inactive polyglycylase TTLL10tubulin tyrosine ligase-like family, member 10tubulin tyrosine ligase-like family, member 5tubulin--tyrosine ligase-like protein 10 | apolipoprotein Eapolipoprotein E3 | |
| Modification date | 20200313 | 20200329 | |
| UniProtAcc | . | P02649 | |
| Ensembl transtripts involved in fusion gene | ENST00000555422, ENST00000298832, ENST00000554510, ENST00000556893, ENST00000557636, ENST00000286650, ENST00000556977, | ENST00000252486, | |
| Fusion gene scores | * DoF score | 22 X 22 X 16=7744 | 5 X 5 X 5=125 |
| # samples | 31 | 5 | |
| ** MAII score | log2(31/7744*10)=-4.64273883200036 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(5/125*10)=-1.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: TTLL5 [Title/Abstract] AND APOE [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | TTLL5(76243193)-APOE(45409057), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | TTLL5 | GO:0018094 | protein polyglycylation | 19524510 |
| Tgene | APOE | GO:0001937 | negative regulation of endothelial cell proliferation | 9685360 |
| Tgene | APOE | GO:0006641 | triglyceride metabolic process | 9649566 |
| Tgene | APOE | GO:0006898 | receptor-mediated endocytosis | 1917954 |
| Tgene | APOE | GO:0007186 | G protein-coupled receptor signaling pathway | 16443932 |
| Tgene | APOE | GO:0007263 | nitric oxide mediated signal transduction | 8995232 |
| Tgene | APOE | GO:0008203 | cholesterol metabolic process | 9649566 |
| Tgene | APOE | GO:0010544 | negative regulation of platelet activation | 8995232 |
| Tgene | APOE | GO:0010873 | positive regulation of cholesterol esterification | 15654758 |
| Tgene | APOE | GO:0010875 | positive regulation of cholesterol efflux | 12042316|14754908 |
| Tgene | APOE | GO:0010976 | positive regulation of neuron projection development | 7592957|23845000 |
| Tgene | APOE | GO:0010977 | negative regulation of neuron projection development | 7592957 |
| Tgene | APOE | GO:0015909 | long-chain fatty acid transport | 24345162 |
| Tgene | APOE | GO:0017038 | protein import | 24446231 |
| Tgene | APOE | GO:0019934 | cGMP-mediated signaling | 8995232 |
| Tgene | APOE | GO:0030195 | negative regulation of blood coagulation | 8995232 |
| Tgene | APOE | GO:0031175 | neuron projection development | 8939961 |
| Tgene | APOE | GO:0032489 | regulation of Cdc42 protein signal transduction | 16443932 |
| Tgene | APOE | GO:0032805 | positive regulation of low-density lipoprotein particle receptor catabolic process | 15950758 |
| Tgene | APOE | GO:0033344 | cholesterol efflux | 11162594|16443932|23620513 |
| Tgene | APOE | GO:0033700 | phospholipid efflux | 11162594 |
| Tgene | APOE | GO:0034372 | very-low-density lipoprotein particle remodeling | 15654758 |
| Tgene | APOE | GO:0034380 | high-density lipoprotein particle assembly | 14754908|17305370 |
| Tgene | APOE | GO:0034382 | chylomicron remnant clearance | 1911868 |
| Tgene | APOE | GO:0034384 | high-density lipoprotein particle clearance | 210175 |
| Tgene | APOE | GO:0034447 | very-low-density lipoprotein particle clearance | 1917954|2762297 |
| Tgene | APOE | GO:0042158 | lipoprotein biosynthetic process | 23620513 |
| Tgene | APOE | GO:0042632 | cholesterol homeostasis | 9649566 |
| Tgene | APOE | GO:0042982 | amyloid precursor protein metabolic process | 21593558 |
| Tgene | APOE | GO:0043254 | regulation of protein complex assembly | 25207746 |
| Tgene | APOE | GO:0043407 | negative regulation of MAP kinase activity | 9685360 |
| Tgene | APOE | GO:0043537 | negative regulation of blood vessel endothelial cell migration | 9685360 |
| Tgene | APOE | GO:0043691 | reverse cholesterol transport | 8127890 |
| Tgene | APOE | GO:0045541 | negative regulation of cholesterol biosynthetic process | 1917954 |
| Tgene | APOE | GO:0045807 | positive regulation of endocytosis | 7683668|8300609 |
| Tgene | APOE | GO:0046889 | positive regulation of lipid biosynthetic process | 12042316 |
| Tgene | APOE | GO:0051000 | positive regulation of nitric-oxide synthase activity | 8995232 |
| Tgene | APOE | GO:0051044 | positive regulation of membrane protein ectodomain proteolysis | 15950758 |
| Tgene | APOE | GO:0055089 | fatty acid homeostasis | 24345162 |
| Tgene | APOE | GO:0060999 | positive regulation of dendritic spine development | 24328732 |
| Tgene | APOE | GO:0071831 | intermediate-density lipoprotein particle clearance | 1917954 |
| Tgene | APOE | GO:0090090 | negative regulation of canonical Wnt signaling pathway | 16805831 |
| Tgene | APOE | GO:0097113 | AMPA glutamate receptor clustering | 24328732 |
| Tgene | APOE | GO:0097114 | NMDA glutamate receptor clustering | 24328732 |
| Tgene | APOE | GO:1900221 | regulation of amyloid-beta clearance | 24446231 |
| Tgene | APOE | GO:1900272 | negative regulation of long-term synaptic potentiation | 16273551 |
| Tgene | APOE | GO:1902430 | negative regulation of amyloid-beta formation | 24154541 |
| Tgene | APOE | GO:1902952 | positive regulation of dendritic spine maintenance | 24328732 |
| Tgene | APOE | GO:1902991 | regulation of amyloid precursor protein catabolic process | 28164773 |
| Tgene | APOE | GO:1902995 | positive regulation of phospholipid efflux | 12042316 |
| Tgene | APOE | GO:1903002 | positive regulation of lipid transport across blood brain barrier | 24345162 |
| Tgene | APOE | GO:1905855 | positive regulation of heparan sulfate binding | 7683668 |
| Tgene | APOE | GO:1905860 | positive regulation of heparan sulfate proteoglycan binding | 8300609 |
| Tgene | APOE | GO:1905890 | regulation of cellular response to very-low-density lipoprotein particle stimulus | 7592957 |
| Tgene | APOE | GO:1905906 | regulation of amyloid fibril formation | 25207746 |
| Fusion gene breakpoints across TTLL5 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene breakpoints across APOE (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | STAD | TCGA-BR-A4IY-01A | TTLL5 | chr14 | 76243193 | + | APOE | chr19 | 45409057 | + |
Top |
Fusion Gene ORF analysis for TTLL5-APOE |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 3UTR-5UTR | ENST00000555422 | ENST00000252486 | TTLL5 | chr14 | 76243193 | + | APOE | chr19 | 45409057 | + |
| 5CDS-5UTR | ENST00000298832 | ENST00000252486 | TTLL5 | chr14 | 76243193 | + | APOE | chr19 | 45409057 | + |
| 5CDS-5UTR | ENST00000554510 | ENST00000252486 | TTLL5 | chr14 | 76243193 | + | APOE | chr19 | 45409057 | + |
| 5CDS-5UTR | ENST00000556893 | ENST00000252486 | TTLL5 | chr14 | 76243193 | + | APOE | chr19 | 45409057 | + |
| 5CDS-5UTR | ENST00000557636 | ENST00000252486 | TTLL5 | chr14 | 76243193 | + | APOE | chr19 | 45409057 | + |
| intron-5UTR | ENST00000286650 | ENST00000252486 | TTLL5 | chr14 | 76243193 | + | APOE | chr19 | 45409057 | + |
| intron-5UTR | ENST00000556977 | ENST00000252486 | TTLL5 | chr14 | 76243193 | + | APOE | chr19 | 45409057 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for TTLL5-APOE |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for TTLL5-APOE |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:76243193/:45409057) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | APOE |
| FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:6860692, PubMed:1911868, PubMed:14754908). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:6860692, PubMed:2762297, PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:14754908, PubMed:23620513). Apoliproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:6860692, PubMed:2762297, PubMed:9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:6860692, PubMed:1911868). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:2762297, PubMed:1917954, PubMed:7768901, PubMed:8939961, PubMed:12950167, PubMed:20030366, PubMed:2063194, PubMed:8756331, PubMed:20303980, PubMed:1530612, PubMed:7635945). Finally, APOE has also a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:9395455, PubMed:9488694, PubMed:23676495, PubMed:7635945). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:23676495, PubMed:29516132). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:2762297, PubMed:29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:2762297, PubMed:1917954, PubMed:29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:9395455, PubMed:14754908, PubMed:23620513). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:8939961, PubMed:25173806). APOE in also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). APOE, may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:28111074). {ECO:0000250|UniProtKB:P08226, ECO:0000269|PubMed:12950167, ECO:0000269|PubMed:14754908, ECO:0000269|PubMed:1530612, ECO:0000269|PubMed:1911868, ECO:0000269|PubMed:1917954, ECO:0000269|PubMed:20030366, ECO:0000269|PubMed:20303980, ECO:0000269|PubMed:2063194, ECO:0000269|PubMed:23620513, ECO:0000269|PubMed:23676495, ECO:0000269|PubMed:2762297, ECO:0000269|PubMed:28111074, ECO:0000269|PubMed:6860692, ECO:0000269|PubMed:7635945, ECO:0000269|PubMed:7768901, ECO:0000269|PubMed:8756331, ECO:0000269|PubMed:8939961, ECO:0000269|PubMed:9395455, ECO:0000269|PubMed:9488694, ECO:0000303|PubMed:25173806, ECO:0000303|PubMed:29516132}.; FUNCTION: (Microbial infection) Through its interaction with HCV envelope glycoprotein E2, participates in the attachment of HCV to HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface and to the assembly, maturation and infectivity of HCV viral particles (PubMed:25122793, PubMed:29695434). This interaction is probably promoted via the up-regulation of cellular autophagy by the virus (PubMed:29695434). {ECO:0000269|PubMed:25122793, ECO:0000269|PubMed:29695434}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for TTLL5-APOE |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for TTLL5-APOE |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for TTLL5-APOE |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for TTLL5-APOE |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies